LncRNA MALAT1-related signaling pathways in osteosarcoma
-
Maryam Farzaneh [3] ; Sajad Najafi [1] ; Omid Anbiyaee [2] ; Shirin Azizidoost [4] ; Seyed Esmaeil Khoshnam [5]
-
[1] Shahid Beheshti University of Medical Sciences
Shahid Beheshti University of Medical Sciences
Irán
-
[2] Shiraz University of Medical Sciences
Shiraz University of Medical Sciences
Irán
-
[3] Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
-
[4] Atherosclerosis Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
-
[5] Persian Gulf Physiology Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 25, Nº. 1 (January), 2023, págs. 21-32
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Osteosarcoma (OS) is a common and malignant form of bone cancer, which affects children and young adults. OS is identified by osteogenic differentiation and metastasis. However, the exact molecular mechanism of OS development and progression is still unclear. Recently, long non-coding RNAs (lncRNA) have been proven to regulate OS proliferation and drug resistance. LncRNAs are longer than 200 nucleotides that represent the extensive applications in the processing of pre-mRNA and the pathogenesis of human diseases. Metastasis‐associated lung adenocarcinoma transcript‐1 (MALAT1) is a well-known lncRNA known as a transcriptional and translational regulator. The aberrant expression of MALAT1 has been shown in several human cancers. The high level of MALAT1 is involved in OS cell growth and tumorigenicity by targeting several signaling pathways and miRNAs. Hence, MALAT1 might be a suitable approach for OS diagnosis and treatment. In this review, we will summarize the role of lncRNA MALAT1 in the pathophysiology of OS.
